Andra AP fonden Buys 58,209 Shares of Illumina, Inc. $ILMN

Andra AP fonden lifted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 56.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 160,700 shares of the life sciences company’s stock after acquiring an additional 58,209 shares during the quarter. Andra AP fonden owned about 0.11% of Illumina worth $15,262,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in ILMN. Loomis Sayles & Co. L P lifted its holdings in Illumina by 1.9% in the 2nd quarter. Loomis Sayles & Co. L P now owns 4,225,529 shares of the life sciences company’s stock worth $403,158,000 after purchasing an additional 78,317 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Illumina by 55.3% in the second quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock valued at $313,290,000 after purchasing an additional 1,174,295 shares during the period. Geode Capital Management LLC lifted its stake in shares of Illumina by 0.7% in the second quarter. Geode Capital Management LLC now owns 2,869,187 shares of the life sciences company’s stock worth $272,921,000 after buying an additional 21,342 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Illumina by 1.9% during the 2nd quarter. Bank of America Corp DE now owns 1,930,843 shares of the life sciences company’s stock worth $184,222,000 after buying an additional 35,167 shares during the period. Finally, Edmond DE Rothschild Holding S.A. grew its stake in Illumina by 140.1% in the 2nd quarter. Edmond DE Rothschild Holding S.A. now owns 1,428,692 shares of the life sciences company’s stock valued at $136,312,000 after buying an additional 833,750 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Up 5.5%

Shares of NASDAQ ILMN opened at $134.46 on Friday. The business has a fifty day moving average of $135.12 and a two-hundred day moving average of $118.11. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $155.53. The stock has a market cap of $20.56 billion, a PE ratio of 24.67, a PEG ratio of 2.44 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.09. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period last year, the firm posted $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, equities research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on ILMN. Robert W. Baird set a $137.00 target price on shares of Illumina in a research report on Friday, February 6th. Stifel Nicolaus boosted their price objective on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Wall Street Zen raised Illumina from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 14th. Canaccord Genuity Group lifted their price target on Illumina from $130.00 to $150.00 and gave the stock a “hold” rating in a research report on Monday, January 26th. Finally, TD Cowen reissued a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. Six investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $129.69.

Insider Activity at Illumina

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the transaction, the senior vice president owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. The trade was a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Scott M. Davies sold 323 shares of the stock in a transaction on Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the sale, the insider owned 17,887 shares in the company, valued at $2,434,241.83. The trade was a 1.77% decrease in their position. The disclosure for this sale is available in the SEC filing. 2.60% of the stock is owned by insiders.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Launched TruPath Genome and unveiled a NovaSeq X roadmap at AGBT — new product roadmap and platform upgrades can drive future instrument sales and recurring consumable revenue, and management highlighted multiomics/cancer initiatives that improve long‑term growth visibility. Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics
• Positive Sentiment: Illumina Laboratory Services to provide clinical whole‑genome sequencing and interpretation to Florida State University’s pediatric rare disease lab — expands clinical lab services, supports adoption of clinical WGS, and helps generate recurring service revenue. Illumina whole‑genome sequencing technology to accelerate rare disease testing in Florida
• Positive Sentiment: Collaboration with Takara Bio on a single‑cell spatial transcriptomics workflow presented at AGBT — strengthens Illumina’s single‑cell and spatial offerings and complements the company’s multiomics strategy. Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow
• Positive Sentiment: Market/flow-driven momentum: analysts and quant flows have turned more constructive after Illumina’s upbeat 2026 outlook and the completed SomaLogic deal — higher relative strength and above‑average volume are cited as drivers of today’s rally. Illumina jumps 5.5% as momentum builds after upbeat outlook and multiomics push
• Neutral Sentiment: Canaccord reiterated a Hold, noting competitive pressures but that 2026 revenue targets remain intact — keeps near‑term expectations cautious despite longer‑term roadmap. Illumina: Competitive Pressures Mounting but 2026 Revenue Targets Still Intact, Justifying a Hold Rating
• Neutral Sentiment: Competitive context: comparisons to fast‑growing peers (e.g., Tempus) highlight execution risk and the need for Illumina to convert product and multiomics momentum into sustained top‑line growth. TEM vs. ILMN: Which MedTech Stock Offers Greater Upside?
• Neutral Sentiment: Short‑interest data released today shows zero reported short shares (likely a reporting anomaly) and thus offers no clear bearish pressure signal at present.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.